SAB Biotherapeutics Inc. (SABS), a clinical-stage biopharmaceutical company, on Tuesday announced positive topline data from its Phase 1 trial of SAB-142, a potential disease-modifying therapy for Type 1 Diabetes.
The trial, conducted among healthy volunteers, met its primary objectives related to safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics.
SAB-142, a human anti-thymocyte immunoglobulin or hIgG, demonstrated a favorable safety profile with no reports of serum sickness or anti-drug antibodies at the target dose.
The drug also showed sustained immunomodulation and a mechanism of action analogous to rabbit ATG, suggesting significant potential in delaying or preventing the progression of T1D.
SAB Biotherapeutics plans to advance SAB-142 into Phase 2b clinical trials in 2025, focusing on adult and pediatric patients with new-onset Type 1 Diabetes.
The company will present full details of these promising results during an R&D webinar today, January 28, 2025, at 8:00 a.m. ET.
As of September 30, 2024, SAB had cash, cash equivalents, and available-for-sale securities of $30.4 million.
The company expects that additional funds from the exercise of outstanding Tranche B warrants will provide sufficient cash to support its operations through 2026.
SABS closed Monday's (Jan.27 2025) trading at $4.36 up 6.34%. In premarket trading Tuesday, the stock is down 22.01% at $3.40.
For comments and feedback: editorial@rttnews.com